Use our advanced clinical trial search to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. General information about clinical trials is also available. Rectal agents should be avoided in cancer patients at risk of names word whizzle thrombocytopenia, leukopenia, and/or mucositis from cancer and its treatment. In the immunocompromised patient, manipulation of the rectum and anus should be avoided (i.e., no rectal examinations, no suppositories, and no enemas). These actions can lead to the development of anal fissures or abscesses, which are portals of entry for infection.
Theophyllinephenobarbital will decrease the level or effect of theophylline by affecting hepatic enzyme CYP1A2 metabolism. Terbutalinephenobarbital increases and terbutaline decreases sedation. Phenobarbital will decrease the level or effect of terbinafine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Phenobarbital will decrease the level or effect of terbinafine by affecting hepatic enzyme CYP2C9/10 metabolism. Terbinafinephenobarbital will decrease the level or effect of terbinafine by affecting hepatic enzyme CYP1A2 metabolism. Teniposidephenobarbital will decrease the level or effect of teniposide by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
Eletriptanphenobarbital will decrease the level or effect of eletriptan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Phenobarbital will decrease the level or effect of elagolix by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Duvelisibphenobarbital will decrease the level or effect of duvelisib by P-glycoprotein efflux transporter. Phenobarbital will decrease the level or effect of dronabinol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Dronabinol is a CYP3A4 substrate. Dronabinolphenobarbital will decrease the level or effect of dronabinol by affecting hepatic enzyme CYP2C9/10 metabolism.
Belladonna alkaloids and benztropine both decrease cholinergic effects/transmission. Additive anticholinergic adverse effects may be seen with concurrent use. Phenobarbital decreases levels of afatinib by P-glycoprotein efflux transporter. Trihexyphenidylbelladonna alkaloids and trihexyphenidyl both decrease cholinergic effects/transmission. Succinylcholinesuccinylcholine increases and belladonna alkaloids decreases cholinergic effects/transmission. Pyridostigminepyridostigmine increases and belladonna alkaloids decreases cholinergic effects/transmission.
Rimegepantphenobarbital will decrease the level or effect of rimegepant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Ranolazinephenobarbital will decrease the level or effect of ranolazine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Pramlintidepramlintide, belladonna alkaloids. Pexidartinibphenobarbital will decrease the level or effect of pexidartinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Perampanelphenobarbital will decrease the level or effect of perampanel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Pemigatinibphenobarbital will decrease the level or effect of pemigatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism.
For patients receiving exemestane with a potent CYP3A4 inducer the recommended dose of exemestane is 50 mg daily after a meal. Phenobarbital will decrease the level or effect of cabozantinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid coadministration of cabozantinib with strong CYP3A4 inducers.
Caffeinated products, carbonated beverages, and gas-producing foods may contribute to bloating and should be avoided if possible. Smoking and chewing gum lead to more swallowed air and may also increase gas and bloating. Excessive alcohol consumption may lead to increased rectal urgency.